In vivo effects of a potent, selective DPPII inhibitor: UAMC00039 is a possible tool for the elucidation of the physiological function of DPPII

Advances in Experimental Medicine and Biology

Volumn 575, Issue , 2006, Pages 73-85

  Maes, Marie Berthe ^a   Lambeir, Anne Marie ^a   Van Der Veken, Pieter ^a   De Winter, Benedicte ^b   Augustyns, Koen ^a   Scharpé, Simon ^a   De Meester, Ingrid ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84934435924     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-32824-6_8     Document Type: Article

References (75)

1. Araki H, Li Y, Yamamoto Y, Haneda M, Nishi K, Kikkawa R and Ohkubo I, 2001, Purification, molecular cloning, and immunohistochemical localization of dipeptidyl peptidase II from the rat kidney and its identity with quiescent cell proline dipeptidase. J. Biochem. (Tokyo) 129: 279-288.
2. Auget M, Delaflotte S, Chabrier EP and Braquet P, 1989, Comparative effects of endothelin and phorbol 12-13 dibutyrate. Life Sci. 45: 2051-2059.
3. Augustyns K, Bal G, Thonus G, Belyaev A, Zhang XM, Bollaert W, Lambeir AM, Durinx C, Goossens F, Haemers A, 1999, The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Curr Med Chem. 6: 311-327.
4. Billah MM, Chapman RW, Egan RW, Gilchrest H, Piwinski JJ, Sherwood J, Siegel MI, West RE Jr, Kreutner W, 1990, Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine. J Pharmacol Exp Ther. 252: 1090-1096.
5. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM, 1972, Definition and antagonism of histamine H2-receptors. Nature 236: 385-390.
6. Blackman JG, Fastier FN, Patel CM, Wong LC, 1956, Assessment of depressor activity and mydriatic activity of hexamethonium analogues. Br J Pharmacol. 11: 282-288.
7. Bradford, MM, 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing he principle of protein-dye binding. Anal Biochem. 72: 248-254.
8. Brandt I, Lambeir AM, Maes MB, Scharpé S, De Meester I, 2005, Peptide substrates of dipeptidyl peptidases, chapter 1 of this book
9. Cashin CH, Dawson W, Kitchen EA, 1977, The pharmacology of benoxaprofen (2-[4-chlorophenyl]-alpha-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with ntiinflammatory activity apparently unrelated to inhibition of prostaglandin synthesis. J Pharm Pharmacol. 29: 330-336.
10. Chen G, Bohner B, Ensor CR, 1954, Evaluation of five methods for testing anticonvulsant activities. Proc Soc Exp Biol Med. 87: 334-339.
11. Chiravuri M, Schmitz T, Underwood R, Yardley K, Dayal, Y and Huber BT, 1999, A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. J Immunol. 163: 3092-3099.
12. D'Amour FE and Smith DL, 1941, A method for determining loss of pain sensation. J Pharmacol Exp Ther. 72: 74-79.
13. Deacon CF, Ahrén B and Holst JJ, 2004, Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig. Drugs 13: 1091-1102.
14. Dejana E, Callioni A, Quintana A, de Gaetano G, 1979, Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb Res. 15: 191-197.
15. Dunham NW, Miya TS, 1957, A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc (Baltim). 46: 208-209.
16. Eisenhauer DA and McDonald JK, 1986, A novel dipeptidyl peptidase II from the porcine ovary. Purification and characterization of a lysosomal serine protease showing enhanced specificity for prolyl bonds. J Biol Chem. 261: 8859-8865.
17. Erjavec F, Adamic S, 1965, Cardiotonic and active transport-inhibiting action of some cardiotonic glycosides and ivorine. Arch Int Pharmacodyn Ther. 155: 251-261.
18. Freundt KJ, 1965, Adrenergic alpha- and beta-receptors in the mouse iris. Nature 206: 725-726.
19. Fukasawa K, Fukasawa KM, Hiraoka BY and Harada M, 1983, Purification and properties of dipeptidyl peptidase II from rat kidney. Biochim Biophys Acta. 745: 6-11.
20. Ganapathy V, Leibach FH, 1986, Carrier-mediated reabsorption of small peptides in renal proximal tubule. Am J Physiol. 251(6 Pt 2): F945-53.
21. Gardner CJ, Twissell DJ, Coates J, Strong P, 1994, The effects of GR79236 on plasma fatty acid concentrations, heart rate and blood pressure in the conscious rat. Eur J Pharmacol. 257: 117-121.
22. Goose J, Blair AM, 1969, Passive cutaneous anaphylaxis in the rat, induced with two homologous reagin-like antibodies and its specific inhibition with disodium cromoglycate. Immunology. 16: 749-760.
23. Gossrau R and Lojda Z, 1980, Study on dipeptidylpeptidase II (DPP II). Histochemistry. 70: 53-76.
24. Gossrau R, 1983, Peptide and protein handling by proteases in the kidney of laboratory rodents. Acta Histochem Suppl. 28: 285-293.
25. Gossrau R, 1991, Histochemical and biochemical studies of dipeptidyl peptidase I (DPP I) in laboratory rodents. Acta Histochem. 91: 85-100.
26. Groneberg DA, Doring F, Nickolaus M, Daniel H, Fischer A, 2002, Renal assimilation of short chain peptides: visualization of tubular peptide uptake. Pharm Res. 19: 1209-1214.
27. Gylys JA, Muccia PM, Taylor MK, 1963, Pharmacological and toxicological properties of 2-methyl-3-piperidinopyrazine, a new antidepressant. Ann N Y Acad Sci. 107: 899-913.
28. Hagiwara M, Watanabe H, Kawata K, Watanabe K, 1984, A novel method of measurement of gastric acid secretion in intact and conscious rats. Yakugaku Zasshi. 104: 1090-1094.
29. Hamilton TC, Weir SW, Weston AH, 1986, Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol. 88: 103-111.
30. Hirotsu I, Kihara T, Hattori Y, Hatta M, Hirose N, Ishihara T, Satoh F, 1988, General pharmacological studies on N-(2,6-dimethylphenyl)-8- pyrrolizidineacetamide hydrochloride hemihydrate. 2nd communication: effect on the peripheral nervous system and peripheral organs. Arzneimittelforschung 38: 1410-1417.
31. Ho RS, Aranda CG, 1979, The influence of 2,2-dimethyl-1-(4-methylphenyl)- 1-propanone (SaH 50-283) on food efficiency in rats. Arch Int Pharmacodyn Ther. 237: 98-109.
32. Hopsu-Havu VK, Jansen CT and Jarvinen M, 1970, Partial purification and characterization of an acid dipeptide naphthylamidase (carboxytripeptidase) of the rat skin. Arch Klin Exp Dermatol. 236: 282-296.
33. Irwin S., 1968, Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13: 222-257.
34. Jiaang WT, Chen YS, Hsu T, Wu SH, Chien CH, Chang CN, Chang SP, Lee SJ, Chen X, 2005, Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett. 15: 687-691.
35. Lambeir AM, Durinx C, Scharpe S, De Meester I, 2003, Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 40: 209-294.
36. Lankas G, Leiting B, Roy RS, Eiermann G, Biftu T, Kim D, Ok H, Weber A and Thornberry NA, 2004, Inhibition of DPP8/9 results in toxicity in preclinical species: potential importance of selective dipeptidyl peptidase IV inhibition for the treatment of Type 2 DM. Diabetes (suppl. 2); 53: A2, 7-OR (Abstract)
37. Lee CH, Strosberg AM, Roszkowski AP, Warren LA, 1982, A model for evaluation of postural hypotension induced by drugs in conscious restrained normotensive rats. J Pharmacol Methods. 7: 15-24.
38. Leibowitz M, Gordon RJ, Wolf PS, Sonnino-Goldman P, 1984, In vivo anti-allergic and Bronchopulmonary pharmacology of REV 3164 in rats and guinea-pigs. Arch Int Pharmacodyn Ther. 271: 135-154.
39. Leiting B, Pryor KD, Wu JK, Marsilio F, Patel RA, Craik CS, Ellman JA, Cummings RT and Thornberry NA, 2003, Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem J. 371: 525-532.
40. Lippmann W, Pugsley TA, 1977, Effects of 3,4-dihydro-lH-1,4-oxazino[4,3- a] indoles, potential antidepressants, on biogenic amine uptake mechanisms and related activities. Arch Int Pharmacodyn Ther. 227: 324-342.
41. Lipschitz WL, Hadidian Z and Kerpcsar A, 1943, Bioassay of diuretics. J Pharmacol Exper Ther. 79: 97-110.
42. Lotti VJ, Cerino DJ, Kling PJ, Change RS, 1986, A new simple mouse model for the in vivo evaluation of cholecystokinin (CCK) antagonists: comparative potencies and durations of action of nonpeptide antagonists. Life Sci. 39: 1631-1638.
43. Lotti VJ, Chang RS, 1989, A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol. 162: 273-280.
44. Lynn KR, 1991, The isolation and some properties of dipeptidyl peptidases II and III from porcine spleen. Int J Biochem. 23: 47-50.
45. Maes MB, Lambeir AM, Gilany K, Senten K, Van der Veken P, Leiting B, Augustyns K, Scharpé S, De Meester I, 2005, Kinetic investigation of human dipeptidyl peptidase II mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase/dipeptidyl peptidase 7. Biochem J. 386: 315-324.
46. McDonald JK, Reilly TJ, Zeitman BB and Ellis S, 1968, Dipeptidyl arylamidase II of the pituitary. Properties of lysylalanyl-beta-naphthylamide hydrolysis: inhibition by cations, distribution in tissues, and subcellular localization. J Biol Chem. 243: 2028-2037.
47. McDonald JK, Leibach FH, Grindeland RE and Ellis S, 1968, Purification of dipeptidyl aminopeptidase II (dipeptidyl arylamidase II) of the anterior pituitary gland. Peptidase and dipeptide esterase activities. J Biol Chem. 243: 4143-4150.
48. McDonald JK and Schwabe C, 1980, Dipeptidyl peptidase II of bovine dental pulp. Initial demonstration and characterization as a fibroblastic, lysosomal peptidase of the serine class active on collagen-related peptides. Biochim Biophys Acta. 616: 68-81.
49. McIntyre JA and Castaner J, 2004, Talabostat. Oncolytic, hematopoietic agent, dipeptidyl-peptidase IV (CD26) inhibitor, fibroblast activation protein inhibitor. Drugs of the Future 29: 882-886.
50. Mentlein R and Struckhoff G, 1989, Purification of two dipeptidyl aminopeptidases II from rat brain and their action on proline-containing neuropeptides. J Neurochem. 52: 1284-1293.
51. Mentlein R, 1999, Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 85: 9-24.
52. Neuworth MB, Louter RJ, Barnhart JW, Sefranka JA, McIntosh DD, 1970, Synthesis and hypocholesterolemic activity of alkylidenedithio bisphenols. J Med Chem. 13: 722-729.
53. Nwangwu PU, Holcslaw TL, Stohs SJ, 1977, A rapid in vivo technique for preliminary screening of antiarrhythmic agents in mice. Arch Int Pharmacodyn Ther. 229: 219-226.
54. Omosu M, Komine I, Becker RH, Scholkens BA, 1988, General pharmacology of ramipril. Arzneimittelforschung 38: 1309-1317.
55. Paton WD, Zar MA, 1968, The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol. 194: 13-33.
56. Protais P, Costentin J, Schwartz JC, 1976, Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology (Berl) 50: 1-6.
57. Robert A, Nezamis JE, Lancaster C, Hanchar AJ, 1979, Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 77: 433-43.
58. Root MA, Sigal MV Jr, Anderson RC, 1959, Pharmacology of 1-(p-chlorobenzenesulfonyl)-3-n-propylurea (chlorpropamide). Diabetes. 8: 7-13.
59. Rosenblum JS, Kozarich JW, 2003, Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol. 7: 496-504.
60. Saxena PR, Lawang A, 1985, A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors. Arch Int Pharmacodyn Ther. 277: 235-252.
61. Schurr PE, Schultz JR, Day CE, 1976, High volume screening procedures for hypobetalipoproteinemic activity in rats. Adv Exp Med Biol. 67(00): 215-229.
62. Sedo A, Malik R, 2001, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta. 1550: 107-116.
63. Sentandreu MA and Toldrá F, 2001, Partial purification and characterisation of dipeptidyl peptidase II from porcine skeletal muscle. Meat Science 57: 93-103.
64. Senten K, Van der Veken P, Bal G, De Meester I, Lambeir AM, Scharpé S, Bauvois B, Haemers A, Augustyns K, 2002, Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg Med Chem Lett. 12: 2825-2828.
65. Senten K, Van Der Veken P, De Meester I, Lambeir AM, Scharpé S, Haemers A, Augustyns K, 2004, Gammaamino-substituted analogues of 1-[(S)-2,4-diaminobutanoyl]piperidine as highly potent and selective dipeptidyl peptidase II inhibitors. J Med Chem. 47: 2906-2916.
66. Siegmund E, Cadmus R, Lu G, 1957, A method for evaluating both non-narcotic and narcotic analgesics. Proc Soc Exp Biol Med. 95: 729-731.
67. Sippel H, Estler CJ, 1990, Comparative evaluation of hepatotoxic side effects of various newtrypanocidal diamidines in rat hepatocytes and mice. Arzneimittelforschung. 40: 290-293.
68. Trolin G, 1975, Effects of pentobarbitone and decerebration on the clonidine-induced circulatory changes. Eur J Pharmacol. 34: 1-7.
69. Turner R, 1965, Depressants of the central nervous system in Screening methods in pharmacology, volume I, pp. 69-86, Academic Press, New York.
70. Underwood R, Chiravuri M, Lee H, Schmitz T, Kabcenell AK, Yardley Kand Huber BT, 1999, Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem. 274: 34053-34058.
71. Vanhoof G, Goossens F, De Meester I, Hendriks D, Scharpé S, 1995, Proline motifs in peptides and their biological processing. FASEB J. 9:736-744.
72. Wasserman MA, Griffin RL, 1977, Thromboxane B2-comparative bronchoactivity in experimental systems. Eur J Pharmacol. 46: 303-313.
73. Wilson C, Buckingham RE, Mootoo S, Parrott LS, Hamilton TC, Pratt SC and Cawthorne MA, 1988, In vivo and in vitro studies of cromokalim (BRL 34915) and glibenclamide in the rat. Br J Pharmacol. 93: 126p.
74. Winter CA, Risley EA, Nuss GW, 1962, Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med. 111: 544-547.
75. Yen TT, Pearson DV, Powell CE, Kirschner GL, 1978, Thermal stress elevates the systolic